At what market price would buying or selling $CLRB make sense to you?
#CLRB
At what market price would buying or selling $CLRB make sense to you?
#CLRB
• Holder: Balyasny Asset Management
• Stake: 9.99%, unchanged (about $1M)
• Filed: Nov 16 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: Balyasny Asset Management
• Stake: 9.99%, unchanged (about $1M)
• Filed: Nov 16 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
On November 10, 2026, we issued a press release announcing our financial results for the quarter ended September 30, 2026, and provided a corporate update.
On November 10, 2026, we issued a press release announcing our financial results for the quarter ended September 30, 2026, and provided a corporate update.
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-third-quarter-2026-financial-results-7e5pn3z2qyaz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-third-quarter-2026-financial-results-7e5pn3z2qyaz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-present-three-posters-highlighting-durable-8qrhsmk49gk8.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-present-three-posters-highlighting-durable-8qrhsmk49gk8.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-report-third-quarter-financial-results-and-tmjxro30mj5d.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-report-third-quarter-financial-results-and-tmjxro30mj5d.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-case-study-highlighting-complete-1utbiitage9y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-case-study-highlighting-complete-1utbiitage9y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-presents-compelling-efficacy-data-from-phase-44orum7awvmw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-presents-compelling-efficacy-data-from-phase-44orum7awvmw.html?utm_source=stocktitan-bluesky&utm_medium=social
comm for @gigigulp.bsky.social
comm for @gigigulp.bsky.social
Cellectar Biosciences has received a major analyst upgrade to Buy. Explore the clinical pipeline, market potential, and what this rating shift means for investors.
Read more: https://insightginie.com/cellectar-bio
Cellectar Biosciences has received a major analyst upgrade to Buy. Explore the clinical pipeline, market potential, and what this rating shift means for investors.
Read more: https://insightginie.com/cellectar-bio
www.youtube.com/watch?v=cLRB...
www.youtube.com/watch?v=cLRB...
$0113.HK: take-private by controlling family for HK$7.2
$AIRX.OL: strategic review
$SNAX: strategic review
$RGLS: acquisition by $NOVN.SW/$NVS for $7+CVR
$CLRB: strategic review
$0113.HK: take-private by controlling family for HK$7.2
$AIRX.OL: strategic review
$SNAX: strategic review
$RGLS: acquisition by $NOVN.SW/$NVS for $7+CVR
$CLRB: strategic review
#Analyst #Articles #- #Estimates #Banking
Origin | Interest | Match